Why I’m pivoting to TechBio $RXRX while everyone is distracted by the Powell investigation and $4600 Gold.

Everyone is worried that the Powell investigation will pose an unprecedented challenge to the Fed's independence, and that a credibility crisis could trigger a systemic downgrade in the United States assets , I wanna say, trading stocks from a macro perspective is no different from throwing darts to pick stocks. This shit didn’t prevent $GOOG from breaking through 4 trillion today. Clearly, we cannot expect a $4-trillion company to grow by another Doble. However, the deepening of NVIDIA's cooperation in AI drug research will definitely enable the stocks with the greatest growth potential and explosive power to more than double in size. Which ONE ? $LLY is indeed the "king of industrialization" of AI pharmaceuticals, and has reached a strategic agreement with Nvidia for a joint investment of $1 billion, but there will be no surprises if it is already Prcie in, and I won't go to places with a lot of people. $ILMN is indeed a good alternative, it provides the genomic data needed for AI evolution, and has successfully transformed from a hardware supplier to an AI data service provider, and its business model is transforming to high-profit software and services, but it has doubled from the bottom and is also priced in. So, who will be the next target for capital inflow? I belive $RXRX is the best choice. It is not crowded at present, has stopped falling in the low demand zone, and its share price is also reasonable. Once the rotation reaches $RXRX, there is still a chance to double at least. Recursion is Nvidia's "core ally" and a direct equity investment in AI-driven pharmaceutical research. Its Recursion OS is a closed-loop system that integrates vast amounts of proprietary biological imaging data, which represents its core competitive advantage. Recursion is one of the few companies in this sector with a petabyte-scale internal dataset capable of executing AI-driven, closed-loop experiments. Under the leadership of CEO Chris Gibson, $RXRX has strategically focused its efforts on "translating biology into search problems," aligning closely with the logic of Google and Nvidia. Most importantly, $RXRX has a substantial cash reserve that will last through 2027, and it operates BioHive-2, the industry's most advanced AI supercomputer. I am absolutely committed to supporting $RXRX.